Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411626 · ClinicalTrials.gov registry record
Home Reported Outcomes in PNH
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 128
- Enrollment target
- 1
- Study location
NCT06411626: Recruiting study of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals.
NCT06411626 is a study of Paroxysmal Nocturnal Hemoglobinuria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 128 participants, below the 256-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06411626, a study of Paroxysmal Nocturnal Hemoglobinuria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-Related Quality of Life (HRQoL) experienced by PNH patients. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures, the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL among PNH patients, including those receiving orally administered iptacopan.
Primary Outcome
Primary endpoint will be measured through longitudinal Home Reported Outcomes (HRO) tracking of self-selected symptoms at enrollment and associated changes in severity against self-reported baselines.
Conditions Studied
Interventions
- OTHER PNH-relevant therapies
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2026-06-15 |
What NCT06411626 shows while recruiting
NCT06411626 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 256-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which PNH-relevant therapies is the first listed.
NCT06411626 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06411626 about?
NCT06411626 is a clinical study titled "Home Reported Outcomes in PNH". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-Related Quality of Life (HRQoL) experienced by PNH patients. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-rep...
What is the current status of trial NCT06411626?
This trial is currently recruiting. The enrollment target is 128 participants. The study started on 2024-06-11. Estimated completion is 2026-06-15.
What conditions does trial NCT06411626 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
What interventions are being tested in trial NCT06411626?
The interventions under investigation include: PNH-relevant therapies (OTHER).
Who is sponsoring clinical trial NCT06411626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411626 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06411626's enrollment target sits among peer trials
128 7th of 14 higher than 8 of 14 other Paroxysmal Nocturnal Hemoglobinuria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Nocturnal Hemoglobinuria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The International PNH Interest Group PNH Registry
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
Global PNH Patient Registry
RECRUITING
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
-
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI